Showing results (1321-1330 of 1,373) with videos related to
Sort By:
Pageof 138
Blood|February 16, 2022
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical featuresTitouan Cazaubiel, Xavier Leleu, Aurore Perrot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related deathPhilippe Moreau, Michele Cavo, Pieter Sonneveld, et al.World Journal of Urology|October 28, 2023
Cut-off time for surgery and prediction of orchiectomy in spermatic cord torsion: a retrospective multicentric study over 15 yearsEmilien Seizilles de Mazancourt, Zinnedine Khene, Marc Sbizerra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du MyélomeBruno Royer, Stéphane Minvielle, Momar Diouf, et al.Leukemia|May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trialCharles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.Bone Marrow Transplantation|January 31, 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMTMeral Beksac, Diderik-Jan Eikema, Linda Koster, et al.Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.Cell Reports|July 16, 2020
CD4+ T Cells Recognize Conserved Influenza A Epitopes through Shared Patterns of V-Gene Usage and Complementary Biochemical FeaturesAlexander Greenshields-Watson, Meriem Attaf, Bruce J MacLachlan, et al.The Lancet. Oncology|October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThierry Facon, Shaji K Kumar, Torben Plesner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experienceHervé Avet-Loiseau, Cyrille Hulin, Loic Campion, et al.Pageof 138